Artelo Biosciences’ (ARTL) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Artelo Biosciences (NASDAQ:ARTL) in a research note released on Wednesday, Benzinga reports. They currently have a $5.00 target price on the stock. HC Wainwright also issued estimates for Artelo Biosciences’ Q3 2024 earnings at ($0.41) EPS, Q4 2024 earnings at ($0.52) EPS, FY2024 earnings at ($2.41) EPS and FY2025 earnings at ($1.58) EPS.

Artelo Biosciences Trading Down 3.1 %

Shares of Artelo Biosciences stock opened at $1.30 on Wednesday. The company’s 50-day moving average price is $1.33 and its two-hundred day moving average price is $1.41. Artelo Biosciences has a 52 week low of $1.15 and a 52 week high of $2.98. The stock has a market cap of $4.19 million, a PE ratio of -0.41 and a beta of 1.43.

Artelo Biosciences (NASDAQ:ARTL) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.75) EPS for the quarter, topping the consensus estimate of ($0.85) by $0.10. On average, equities analysts predict that Artelo Biosciences will post -2.09 EPS for the current fiscal year.

About Artelo Biosciences

Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.